Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized comparison of daprodustat vs darbepoetin alfa in anemia due to chronic kidney disease
2016-000507-86Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daprodustat in anemia of renal disease and chronic kidney disease (CKD) (2 arms), sponsored by GSK. Primary endpoint: Primary: Change in hemoglobin. Started Jan 2017; status: completed.
02
Drugs
daprodustat
03
Conditions
anemia of renal diseasechronic kidney disease (CKD)
Beyond the preview
Go deeper on 2016-000507-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000507-86.